Bruker AXS Announces Agreement to Acquire the Princeton Gamma-Tech (PGT) X-Ray Microanalysis Business

Bruker AXS Inc. today announced an agreement to acquire
the PGT X-ray microanalysis business with annual revenues of $5-6
million from Princeton Gamma-Tech Instruments, Inc. The terms of the
transaction were not disclosed, and the acquisition is expected to
close in the fourth quarter of 2005.
   On October 14, 2005, Bruker AXS had announced an agreement to
acquire Roentec AG, an X-ray microanalysis company based in Berlin,
Germany. After the closing of both transactions, Roentec AG and the
PGT Microanalysis Business will be combined into the new 'Bruker AXS
Microanalysis Group', which will focus on the $150 million per annum
global X-ray microanalysis market.
   The PGT microanalysis business features an excellent X-ray
microanalysis product line, with advanced technology, and many
outstanding data acquisition and analysis software features. Moreover,
the PGT microanalysis business has extensive distribution and service
capabilities in the United States, the United Kingdom and France.
   Roentec, a broad-based X-ray instrumentation company, has a
technically leading microanalysis product line with outstanding
detector technology and ultra-fast acquisition electronics. Roentec
also has developed unique mobile systems for the XRF microanalysis of
works of art, as well as novel transportable Total Reflection X-ray
Fluorescence (TXRF) systems for elemental trace analysis in liquids,
e.g. for environmental or beverage analysis. Roentec has established
good distribution and service capabilities in continental Europe, as
well as in selected other countries.
   Roger Durst, Ph.D., Bruker AXS Executive Vice President,
commented: "Roentec and PGT both have excellent technology and
products, and both have a strong customer base in complementary
geographical markets. However, both companies also have been
distribution-limited and at a size disadvantage relative to their
larger competitors. We believe that their combined product line and
software, further enhanced by additional technologies from Bruker AXS,
can offer leading capabilities, as well as extensive service and
support coverage to X-ray microanalysis customers anywhere in the
world."

   Background on X-Ray Microanalysis Market

   The X-ray microanalysis market consists of X-ray accessories for
scanning and transmission electron microscopes, as well as of
stand-alone micro X-ray fluorescence (XRF) spectrometers. X-ray
microanalysis is considered to be one of the faster growing segments
of the overall X-ray analysis market. Applications of X-ray
microanalysis include nanotechnology and advanced materials research,
as well as materials analysis and quality control, with customers in
industry, academia and government research facilities.
   Bruker AXS, a technology and market leader in X-ray diffraction
(XRD) systems for advanced materials and nanotechnology research, in
X-ray single crystal diffraction (SCD crystallography) systems for
small molecule and protein 3D structural analysis, and in X-ray
fluorescence (XRF) elemental analysis for a variety of materials
analysis and quality control applications, so far has not participated
in the X-ray microanalysis market segment. For more information,
please visit www.bruker-axs.com.

   ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker AXS
Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and
provider of life science and advanced materials research tools based
on X-ray technology. Bruker Daltonics is a leading developer and
provider of innovative life science tools based on mass spectrometry.
For more information, please visit www.bruker-biosciences.com.

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our annual
report on Form 10-K for the year ended December 31, 2004, our most
recent quarterly reports on Form 10-Q and our current reports on Form
8-K. We disclaim any intent or obligation to update these
forward-looking statements.